Recombinant Human GALNT3 Protein: Function & Research Use

Recombinant Human GALNT3 Protein is a member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family that catalyzes the initial step of mucin-type O-linked glycosylation, making it an essential reagent for studying glycan biosynthesis, phosphate metabolism disorders, and related signaling pathways.

Protein Name

Recombinant Human GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3)

Gene Name

GALNT3

Protein Family

UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family

Biological Function

Catalyzes transfer of GalNAc from UDP-GalNAc to serine or threonine residues on target polypeptides, initiating mucin-type O-glycosylation

Research Relevance

Associated with familial tumoral calcinosis and hyperostosis-hyperphosphatemia syndrome due to loss-of-function mutations

SKU

rp365518

Biological Background and Function of GALNT3

GALNT3 (Polypeptide N-acetylgalactosaminyltransferase 3) is a Golgi-resident glycosyltransferase enzyme encoded by the GALNT3 gene in humans. It belongs to the large family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts), which collectively initiate the O-glycosylation of mucins and other glycoproteins by transferring N-acetylgalactosamine (GalNAc) from the sugar nucleotide donor UDP-GalNAc onto serine or threonine residues of acceptor polypeptides.

This initial glycosylation event—commonly referred to as the Tn antigen—serves as the foundation for subsequent elaboration of complex O-glycan structures by other Golgi-resident glycosyltransferases. GALNT3 exhibits a distinct substrate specificity compared with other family members, preferentially glycosylating substrates that already carry partial O-glycan modifications, a property that positions it as both an initiating and a follow-up transferase depending on the biological context.

Notably, GALNT3 plays a critical role in regulating phosphate homeostasis. It is responsible for O-glycosylating Fibroblast Growth Factor 23 (FGF23), a hormone that governs renal phosphate reabsorption and vitamin D metabolism. O-glycosylation by GALNT3 protects FGF23 from proteolytic cleavage, allowing the intact, biologically active form of FGF23 to circulate and suppress renal phosphate reabsorption. Loss-of-function mutations in GALNT3 lead to unprocessed, inactive FGF23, resulting in hyperphosphatemia and the pathological conditions familial tumoral calcinosis (FTC) and hyperostosis-hyperphosphatemia syndrome (HHS).

Protein Structure and Biochemical Properties

Like other members of the ppGalNAc-T family, GALNT3 is a type II transmembrane protein with a short N-terminal cytoplasmic tail, a single transmembrane domain, a stem region, and a large C-terminal catalytic domain oriented toward the Golgi lumen. The catalytic region contains a GT-A fold characteristic of glycosyltransferases and coordinates a divalent manganese ion (Mn²⁺) essential for catalytic activity. A conserved DxH motif within the catalytic domain is involved in metal ion coordination and UDP-GalNAc binding.

In addition to the catalytic domain, GALNT3 contains a C-terminal ricin B-type lectin domain. This lectin domain is thought to facilitate enzyme-substrate interactions by binding to existing glycan structures on the acceptor polypeptide, thereby contributing to the enzyme's processivity and substrate preference for partially glycosylated acceptors.

Recombinant Human GALNT3 Protein produced for research use is typically expressed in mammalian or insect cell systems to ensure proper folding, disulfide bond formation, and glycosylation of the enzyme itself, all of which are important for maintaining catalytic activity in vitro. The recombinant protein is generally purified by affinity chromatography and supplied in a formulation buffer compatible with enzymatic assays.

Research Applications

Recombinant Human GALNT3 Protein is employed across a range of experimental contexts in glycobiology, biochemistry, and disease-mechanism research:

• In vitro glycosylation assays: GALNT3 is used to study the transfer of GalNAc onto synthetic peptide substrates or recombinant proteins, enabling characterization of substrate specificity, kinetic parameters (Km, Vmax), and inhibitor screening.
• FGF23 biology and phosphate metabolism: Because GALNT3 O-glycosylates and thereby stabilizes FGF23, the recombinant enzyme is used in studies of FGF23 processing, secretion, and the pathophysiology of disorders such as familial tumoral calcinosis and chronic kidney disease-related mineral metabolism dysregulation.
• Cancer glycobiology: Aberrant O-glycosylation is a hallmark of many epithelial cancers. GALNT3 expression changes have been observed in colorectal, pancreatic, and other carcinomas; the recombinant protein supports mechanistic studies of glycosylation-dependent cancer cell behavior.
• Structural biology: The recombinant protein can serve as an antigen for antibody generation or as a tool for co-crystallization and structural studies aimed at understanding enzyme-substrate recognition.
• Drug discovery: GALNT3 is a potential therapeutic target; the recombinant protein supports high-throughput screening campaigns to identify small-molecule inhibitors or modulators of O-glycosylation pathways.

Handling, Storage, and Quality Considerations

To preserve the activity and integrity of Recombinant Human GALNT3 Protein, researchers should adhere to the following best practices:

• Storage: Store the protein at –80 °C for long-term preservation. Avoid repeated freeze-thaw cycles, which can lead to aggregation and loss of enzymatic activity. Aliquot upon receipt to minimize freeze-thaw events.
• Working concentration: Reconstitute lyophilized preparations according to the manufacturer's certificate of analysis. For liquid formulations, equilibrate to the recommended assay temperature before use.
• Enzymatic assay conditions: GALNT3 activity is typically measured in the presence of a divalent metal cation cofactor (Mn²⁺ or Mg²⁺) and UDP-GalNAc. Confirm optimal pH and buffer conditions from the product datasheet.
• Quality verification: Batch quality is typically confirmed by SDS-PAGE, activity assay (transfer of GalNAc to a known acceptor peptide), and endotoxin testing. Consult the certificate of analysis supplied with each lot.
• Safety: Handle according to standard laboratory practices for recombinant proteins. Consult the Safety Data Sheet (SDS) for disposal and hazard information.

Frequently asked questions

What is the primary enzymatic function of GALNT3?

GALNT3 catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to serine or threonine residues on target polypeptides, representing the initiating step of mucin-type O-linked glycosylation. It also acts as a follow-up transferase on partially glycosylated substrates due to its lectin domain-assisted substrate recognition.

Why is GALNT3 important in phosphate metabolism and what diseases are linked to its deficiency?

GALNT3 O-glycosylates FGF23, a key phosphaturic hormone, protecting it from proteolytic inactivation. When GALNT3 is non-functional, FGF23 is cleaved and inactivated, causing elevated serum phosphate (hyperphosphatemia). This underlies familial tumoral calcinosis (FTC) and hyperostosis-hyperphosphatemia syndrome (HHS), both rare autosomal recessive disorders characterized by ectopic calcification or bone abnormalities.

What expression system is recommended for producing active recombinant GALNT3?

Mammalian cell expression systems (such as HEK293 or CHO cells) or baculovirus-infected insect cell systems are generally preferred for producing recombinant GALNT3, as these systems support proper protein folding, disulfide bond formation, and glycosylation of the enzyme itself. These post-translational modifications are important for full catalytic activity and protein stability.

How should Recombinant Human GALNT3 Protein be stored to maintain activity?

The protein should be stored at –80 °C and aliquoted upon receipt to avoid repeated freeze-thaw cycles. Repeated freeze-thaw events can cause aggregation and significant loss of enzymatic activity. Always refer to the product-specific certificate of analysis for the recommended storage buffer and conditions.

In what types of cancer research is GALNT3 relevant?

Altered GALNT3 expression has been reported in colorectal, pancreatic, and other epithelial carcinomas, where aberrant O-glycosylation contributes to tumor cell behavior, invasion, and immune evasion. Recombinant GALNT3 protein is used to investigate how changes in O-glycosylation patterns affect cancer-related signaling and to identify potential glycosylation-based biomarkers or therapeutic targets.

References

1. Topaz O, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nature Genetics. 2004.
2. Kato K, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. Journal of Biological Chemistry. 2006.
3. Bennett EP, et al. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012.
4. Tian E & Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconjugate Journal. 2009.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.